Kayaker, 

Thanks for your insight and critique of that Seeking Alpha article. I see regardless over on Stockhouse was asking my opinion about Nasdaq timing, potential dilution/consolidation, and near term catalysts. I don't have much to say about the first two, but as for near term catalysts I am expecting:

• more pre-clinical validation of xB3-001 (NHP imaging, microdialysis)
• some details from the pre-IND meeting with FDA for xB3-001
• potentially more details of the WuXi xB3-001 production arrangement
• pre-clinical results of the xB3-002 glioblastoma proof of mechanism studies with Minerva imaging
• publication of the xB3 siRNA work that also details the discovery of xB3/Mtfp as the active peptide of full length MTf
• more details and potentially pre-clinical results of the xB3-007 neurodegenerative disease program

BearDownAZ